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Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignant tumours with a poor prognosis worldwide.
While early stage tumours can be treated with curative approaches such as liver transplantation or surgical resection,
these are only suitable for a minority of patients. Those with advanced stage disease are only suitable for supportive
approaches and most are resistant to the conventional chemotherapy or radiotherapy. Liver cancer stem cells (LCSCs)
are a small subset of cancer cells with unlimited differentiation ability and tumour forming potential. In order to
develop novel therapeutic approaches for HCC, we need to understand how the cancer develops and why treatment
resistance occurs. Using high-throughput sequencing techniques, a large number of dysregulated long noncoding
RNAs (lncRNAs) have been identified, and some of which are closely linked to key aspects of liver cancer pathology,
progression, outcomes and for the maintenance of cancer stem cell-like properties. In addition, some lncRNAs are
potential biomarkers for HCC diagnosis and may serve as the therapeutic targets. This review summarizes data recently
reported lncRNAs that might be critical for the maintenance of the biological properties of LCSCs.
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Background
Although more than 70% of the whole human genome is
transcriptionally very active, only less than 2% of the
transcripts are eventually translated into proteins [1, 2].
Long noncoding RNAs (lncRNAs) are a subclass of func-
tional ncRNAs (tRNA and rRNA are not included in this
review); they are over 200 nucleotides in size and are in-
capable of encoding protein [3, 4]. lncRNAs may share
some characteristics of mRNAs [4]. For instance, lncRNAs
are transcribed by RNA polymerase II; they are 5′ capped,
equipped with 3′ polyA (polyadenylate) tail and consist of
multiple exons [4, 5]. Initially, lncRNAs were thought to
be junk or transcriptional noise since they are not well
conserved across species and because expression levels
were relatively lower compared with mRNAs [5–8].
However, recent studies suggest that lncRNAs play a key
role in many biological processes such as X chromosome
inactivation, cell cycle regulation, and cardiac develop-
ment [4, 5, 9, 10]. lncRNAs are also involved in the devel-
opment of many diseases. For example, using microarray
analysis, a list of dysregulated (either up-regulated or
down-regulated) lncRNAs have been identified in many
tumour types such as prostate, liver, lung, and breast can-
cer [11–18]. Broadly, lncRNAs can be classified as either
oncogenic or tumor-suppressive [19].
Hepatocellular carcinoma (HCC) is a leading cause of
cancer related death worldwide [20, 21], with more than
500,000 new cases reported every year [22]. Early stage
HCC can be effectively treated by liver transplantation or
curative surgery, but for advanced cases, the therapeutic
strategies are limited [23, 24]. Tumour recurrence and
disease relapse after therapy, as well as drug resistance are
the critical issues leading to poor prognosis [24, 25].
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Within the liver tumour bulk, a small group of cells
known as liver cancer stem cells (LCSCs) are considered
to be responsible for the initiation, recurrence and drug
resistance of HCC [26, 27]. How LCSCs are regulated at
the molecular level is not well understood. Knowledge of
the key regulators of LCSC behaviour would facilitate the
development of more effective therapeutic approaches IIn
this regard, increasing evidence has shown that lncRNAs
may be involved in the regulation of the biological func-
tion of LCSCs. For example, multiple lncRNAs are
expressed aberrantly in LCSCs compared to non-cancer
stem cells [28, 29], while some lncRNAs are required for
the self-renewal and tumour propagation of LCSCs [30–
32], or are closely associated with the clinico-pathological
features [8, 33, 34]. However, the precise function of
lncRNAs in LCSCs is poorly defined. This review summa-
rizes current understanding of the lncRNAs and their im-
plications for HCC and LCSCs.
Origin and classification of lncRNA
Unlike mRNA, lncRNAs are not very well conserved across
species [8, 35]. These RNAs may derive from several
sources: (1) insertion of a transposable element; (2) duplica-
tion of noncoding RNA; (3) transformation from a previous
protein coding gene; and (4) chromatin rearrangement
[36–38] (Fig. 1). In fact, lncRNAs can be generated either
from protein coding genes or non-protein coding genes. A
common way of categorizing lncRNAs is based on the rela-
tive position with respect to the closest protein coding gene
in the genome. In this way, lncRNAs can be classified into
the following five categories: (1) intergenic lncRNAs: tran-
scribed from the space between two protein coding genes;
(2) intronic lncRNAs: incorporated inside the intron of a
protein coding gene; (3) sense lncRNAs: transcribed from
the sense strand of a protein coding gene; (4) antisense
lncRNAs: transcribed from the antisense strand of a protein
coding gene, usually overlapping the introns or exons of
the sense strand; and (5) bidirectional lncRNAs: transcribed
in an opposite direction with respect to the nearby protein
coding gene and located within 1 kb from the promoter of
the protein coding gene [8, 38] (Fig. 2).
lncRNAs are involved in HCC through multiple
mechanisms
lncRNAs are present in either nucleus or cytoplasm, and
they can interact with DNA, RNA or protein [39, 40].
Through this, they modulate the expression and stability
of their downstream targets at epigenetic, transcriptional
and post-transcriptional levels [41] (Fig. 3).
At the epigenetic level, lncRNAs can regulate the ex-
pression of target gene via recruiting chromatin modifying
factors to alter chromatin structure [42]. For example, an
up-regulated lncRNA CDKN2B antisense RNA 1 (ANRIL)
in HCC has been demonstrated to promote cell prolifera-
tion; its expression level is positively associated with the
Barcelona Clinic Liver Cancer (BCLC) stage [43]. This
ncRNA is mostly present in the nucleus where it silences
the function of Kruppel-like factor 2 (KLF2) through
recruiting polycomb repressive complex 2 (PRC2) to the
promoter region of KLF2 resulting in H3K27 trimethyla-
tion and KLF2 silencing [43].
lncRNAs are able to modulate the expression of non-
protein coding genes such as microRNAs. In this aspect,
down-regulation of a lncRNA H19 has been shown to play
an important role in HCC metastasis [44]. H19 directly
binds hnRNP U/PCAF/RNA polII complex resulting in
the active transcription of the miR-200 family by acetylat-
ing histone H3 of its promoter [44].
lncRNAs have also been found to function at a post-
transcriptional level to control the progression of HCC
via regulating alternative splicing and mRNA stability
[41]. For example, an up-regulated lncRNA termed
metastasis-associated lung adenocarcinoma transcript 1
(MALAT1) in HCC increases the expression of splicing
factor SRSF1 (serine and arginine rich splicing factor 1)
through activating Wnt pathway, causing dys-regulated
Fig. 1 Multiple origins of lncRNAs. lncRNA may derive from (1) insertion of a transposable element; (2) duplication in non-coding RNA; (3)
a previous protein coding gene; (4) chromatin rearrangement [36–38]
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apoptosis and alternative splicing of S6 kinase1 (S6 K1),
which further activates the mTOR pathway, and ultim-
ately resulting in HCC progression [45].
Antisense lncRNAs can affect the stability of mRNAs. For
example, an up-regulated antisense lncRNA termed PCNA
antisense RNA 1 (PCNA-AS1) in HCC has been shown to
prompt tumor growth by forming a RNA duplex with prolif-
erating cell nuclear antigen (PCNA), leading to alteration of
PCNA structure and increase in its stability [46].
Studies over the recent years have also revealed that
lncRNAs can act as competing endogenous RNAs (ceR-
NAs) and play important roles in HCC [47]. In this
perspective, an over-expressed lncRNA in HCC termed
colon cancer associated transcript 1 (CCAT1) was found
to competitively bind to let-7 (as evidenced by increased
expression of let-7 target genes including high mobility
group AT-hook2 and c-Myc), leading to increased prolif-
eration and migration of HCC cells [48]. Similarly, a newly
identified lncRNA unigene56159 also functions as a
ceRNA [49]. Unigene56159 is significantly up-regulated in
HBV-related HCC tissues, and is required for epithelial-
mesenchymal transition (EMT) and migration of HCC
cells by acting as a ceRNA for miR-140-5p to increase the
expression of Slug [49].
Fig. 2 Classification of lncRNAs. Multiple type of lncRNAs have been identified, including (1) Sense lncRNA: transcribed from the sense strand of a
protein coding gene; (2) Antisense lncRNA: transcribed from the antisense strand of a protein coding gene, usually overlapping the introns or
exons of the sense strand; (3) Intergenic lncRNA: transcribed from the space between two protein coding genes; (4) Intronic lncRNA: incorporated
inside of the introns of protein coding genes; (5) Bidirectional lncRNA: transcribed in an opposite direction with respect to the nearby protein
coding gene and located within 1 kb of the promoter of the protein coding gene [8, 38]
Fig. 3 Mechanism of lncRNA function. lncRNAs are involved in HCC development through multiple mechanisms. (1) At the epigenetic level,
lncRNAs can regulate the expression of target genes via recruiting chromatin modifying factors to alter chromatin structure [42]; (2) lncRNAs can
control the process of alternative splicing [41]; (3) lncRNAs can regulate mRNA stability [41]; (4) lncRNAs can act as competing endogenous RNAs
(ceRNAs) [47]
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HCC associated lncRNA
By microarray or next-generation sequencing, a large
number of significantly dysregulated lncRNAs have been
identified in HCC tumour tissues as compared with
adjacent non-tumorous liver [50]. Below, we will
summarize some of the deregulated lncRNAs that may
play key roles in HCC development and progression,
and describe their correlation with the clinical outcomes
of HCC. The reported data may provide new sights for
the early diagnosis and for therapeutic targeting.
Dysregulated lncRNAs implicated in the
regulation of HCC proliferation
Deregulated control of the ability to proliferate and
undergo apoptosis is an important feature of cancers
[51]. Many lncRNAs are involved in the regulation of
uncontrolled cell growth in HCC. TP73 antisense RNA
1 (TP73-AS1) is a lncRNA that is overexpressed in HCC
tissues compared to the adjacent non-tumorous liver
[52]. TP73-AS1 competes with high mobility group box 1
(HMGB1) to bind miR200a and activates HMGB1/
RAGE axis thereby promoting the proliferation of HCC
cells [52]. As such, knockdown of TP73-AS1 by siRNA
leads to impaired proliferation and colony formation of
HepG2 and HCCLM3 cells [52].
Colon cancer associated transcript 2 (CCAT2) is an
oncogenic lncRNA transcribed from chromosome
8q24.21 [53]. Up-regulation of CCAT2 has been identi-
fied in several HCC cell lines (HepG2, Hep3B, HCCLM3
and Huh7) and tumour tissues [53]. Overexpression of
CCAT2 in HepG2 and Huh7 cells significantly promotes
their proliferation while apoptosis is reduced [53]. Op-
posite results were observed when CCAT2 was knocked
down in these cells [53].
lncRNAs may perform their biological functions via
interacting with other proteins. For example, overexpres-
sion of a lncRNA termed ultraconserved element 338
(uc.338) was shown to promote the proliferation of HCC
cells in a BMI1-dependent manner as confirmed by RNA
pull down and RNA immunoprecipitation assays [54].
In addition to up-regulated lncRNAs, some significantly
down-regulated lncRNAs play critical roles in HCC. For
example, significantly reduced expression of lncRNA
BRAF-activated noncoding RNA (BANCR) has been ob-
served in HCC tissues and HCC cell lines (Huh7, HepG2
and SMMC-7721). Consequently, forced overexpression
of lncRNA BANCR in these cells inhibits their prolifera-
tion in vitro and in vivo [55]. Another down-regulated
lncRNA termed long noncoding RNA FTX (lnc-FTX) in
HCC can modulate the proliferation of HCC and is closely
related with the prognosis [56]. Thus, lnc-FTX itself
functions as a tumor suppressor by interacting with mini-
chromosome maintenance protein 2 (MCM2), suppress-
ing the proliferation of HCC cells. In addition, lnc-FTX
may function as a ceRNA by binding to miR-374a, thereby
inhibiting the activity of Wnt pathway and decrease in
EMT and invasion [56]. Patients with low hepatic lnc-FTX
have reduced survival and early recurrence suggesting that
lnc-FTX might serve as a biomarker of prognosis [56].
LncRNAs involved in the regulation of epithelial
to mesenchymal transition in HCC
Previous studies have confirmed that epithelial to mesen-
chymal transition (EMT) contributes to multiple stages of
cancer development such as progression, invasion and
metastasis [57]. Increasing evidence now demonstrates
that many lncRNAs play a role in triggering EMT during
the pathogenesis of HCC. For instance, up-regulation of a
lncRNA urithelial carcinoma-associated 1 (UCA1) in
HCC tissues has been closely linked to tumour size, inva-
sion and tumour progression [58]. In vitro studies also
suggested significant up-regulation of lncRNA UCA1 in
multiple HCC cell lines (Huh7, SK-Hep-1, MHCC97H
and MHCC97L) [58]. By using gain- and lose-of-function
analysis in MHCC97H and MHCC97L cells, a positive
correlation between the expression of lncRNA UCA1 and
EMT markers such as Snail2 and Vimentin was identified,
as well as a negative correlation between the expression of
lncRNA UCA1 and E-cadherin [58]. These data suggest
that overexpression of lncRNA UCA1 may promote HCC
development by driving EMT [58]. As mentioned above,
CCAT2 is a lncRNA up-regulated in HCC and high level
of lncRNA CCAT2 correlates with poorer patient survival
and a worse prognosis [59]. This lncRNA not only pro-
motes the proliferation of HCC cells, but also activates
EMT via up-regulating Snail2 [59]. Similarly, two other
lncRNAs Sprouty4-Intron 1 (SPRY4-IT1) and small nucle-
olar RNA host gene 20 (SNHG20) that are overexpressed
in HCC have been shown to prompt EMT via up-
regulating the transcription factors twist1 and Vimentin
while reducing the expression of E-cadherin [60–62].
Role of lncRNAs in HCC drug resistance
Resistance to chemotherapy or radiotherapy is a serious
hurdle in the clinical management of patients with HCC.
Indeed, resistance to previously first-line anticancer agents
like adriamycin is responsible for a large portion of treat-
ment failure in patients with advanced liver cancer [63–65].
Multiple studies have revealed that some lncRNAs may be
mechanistically responsible for the development of antican-
cer drug resistance in HCC.
Taurine up-regulated gene 1 (TUG1) is an overexpressed
lncRNA present in adriamycin-resistant HCC tissues and
cell lines (SMMC-7721/ADM and HepG2/ADM). In turn,
siTUG1 mediated knockdown of TUG1 restored the sensi-
tivity of resistant cells to adriamycin [65]. Mechanistically,
TUG1 was found to regulate the expression of P-
glycoprotein (P-gp) and multidrug-resistance 1 (MDR1)
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which are closely related to the development of drug resist-
ance [65].
Although the mechanism of drug resistance is not well
understood, protective autophagy has been proposed to
be involved in chemoresistance [66, 67]. Highly up-
regulated in liver cancer (HULC) RNA is another com-
monly up-regulated lncRNA in HCC [67]. Up-regulation
of HULC has been linked to the development of resist-
ance of HCC cells to oxaliplatin, 5-fluorouracil (5-FU)
and pirarubicin (THP) via activating autophagy by pro-
tecting the degradation of silent information regulator 1
(SIRT1) [67]. This finding suggests that HULC may be a
novel target for improving the chemosensitivity [67].
Role of lncRNAs in the regulation of liver cancer
stem cells (LCSCs)
Although LCSCs only represent a small portion of cells
within HCCs, they are a critical subset of cells that are
believed to account for the initiation, progression, recur-
rence, metastasis and treatment resistance of liver cancer
[26, 27]. An increasing number of dysregulated lncRNAs
have been identified in LCSCs. Among them, a range of
lncRNAs directly regulate the stem cell features or indir-
ectly regulate LCSCs via interacting with other key sig-
naling pathways, such as Wnt and IL6/STAT3 pathways
[68]. Some identified lncRNAs involved in the regulation
of the function of LCSCs are summarized below.
HOX antisense intergenic RNA (HOTAIR)
HOX antisense intergenic RNA (HOTAIR) is a 2.2 kb
lncRNA localized to chromosome 12q13.13 within
Homeobox C (HOXC) cluster [69, 70]. The oncogenic
role of HOTAIR has been demonstrated in multiple can-
cers such as breast cancer, melanoma, and colorectal
cancer [19, 71, 72]. Up-regulation of HOTAIR has also
been identified in HCC [73] and LCSCs where it has
been linked to the expansion of stem cells. Mechanistic-
ally, HOTAIR reduces the recruitment of P300, RNA
polymerase II (RNApol II) and cAMP responsive elem-
ent binding protein 1 (CREB) to the promoter of SET
Domain-Containing Protein 2 (SETD2) thereby sup-
pressing SETD2 activity [73]. Reduced SETD2 activity
impairs the binding to histone 3 (H3) and subsequently
leads to reduced trimethylation on histone H3 thirty-
sixth lysine (H3K36me3), resulting in reduced formation
of the H3K36me-hMSH2-hMSH6-SKP2 complex. These
changes eventually disrupt DNA damage repair mecha-
nisms and cause microsatellite instability (MSI) [73].
Lnc-DILC
Lnc-DILC is a recently identified novel lncRNA with tumor
suppressive activity [28]. By microarray and qRT-PCR ana-
lysis, reduced expression of lnc-DILC has been observed in
LCSCs [28]. Using RNA in situ hybridization, lnc-DILC
was found to reside in both the nucleus and cytoplasm
[28]. In vivo and in vitro experiments demonstrate that lnc-
DILC suppresses the expansion of LCSCs via inhibiting
interleukin 6 (IL-6)/JAK2/STAT3 signaling [28]. Using
multivariate analysis, it was found that lnc-DILC may serve
as an independent prognostic marker for HCC. Thus, pa-
tients with low hepatic expression have shorter survival
time and a higher frequency of tumour recurrence than
those with higher lnc-DILC levels [28]. These data indicate
that lnc-DILC could serve as a potential target for HCC
therapy and as a biomarker for monitoring outcome.
LncBRM
LINCR-0003 (lncBRM) is a lncRNA overexpressed in
HCC tissues and LCSCs; it is required for the mainten-
ance of the stemness features and for the biological
properties of LCSCs through Yes-associated protein 1
(YAP1) signaling [29]. LncBRM is present in the cell nu-
cleus and is localized between actin beta like 2
(ACTBL2) and polo like kinase 2 (PLK2) on chromo-
some 5, with a size of 1321 nt containing six exons [29].
By RNA pulldown assay, lncBRM interactt with BRM
and this interaction facilitates the formation of BRG1-
embedded BAF (BRG1-associated factor) complex. The
latter can then bind to the promoter region of YAP1 and
along with the enrichment of KLF4, ultimately leads to
activation of YAP1 signaling, a critical pathway for the
maintenance of stemness features of LCSCs [29].
Cancer up-regulated drug resistant (CUDR)
Cancer up-regulated drug resistant (CUDR) is an up-
regulated oncogenic lncRNA in LCSCs [74]. CUDR is
present in both the nucleus and cytoplasm and exerts its
biological function by promoting the growth of LCSCs
through up-regulating the expression of CyclinD1 and
down-regulating phosphatase and tensin homolog (PTEN).
This promotes the formation of a CUDR-CyclinD1 com-
plex [74] that inhibits the methylation of H19 promoter, in-
creases H19 transcription and increases the formation of
telomerase reverse transcriptase-telomerase RNA compo-
nent (TERT-TERC) complex, thereby leading to increased
telomerase activity [74]. In addition, the CUDR-CyclinD1
complex can be recruited by CCCTC-binding factor
(CTCF) to form a CUDR-CyclinD1-CTCF complex which
can engage the promoter of c-Myc leading to increased c-
Myc expression [74]. These changes synergistically contrib-
ute to the expansion of LCSCs [74].
LncTCF7
Wnt signaling has been confirmed to play an important
role in the self-renewal and propagation of CSCs [75]. Re-
cently, an intergenic lncRNA termed lncTCF7 was found
to activate the Wnt pathway in LCSCs by modulating its
nearby gene expression [30]. lncTCF7 is present in the
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nucleus and is up-regulated in HCCs and LCSCs [30].
lncTCF7 sustains the self-renewal of LCSCs by recruiting
SWItch/Sucrose Non-Fermentable (SWI/SNF) complex
to the promoter of its nearby protein coding gene
transcription factor 7 (TCF7) leading to increased TCF7
transcription and activation of Wnt signaling pathway
[30]. Of note, lncTCF7 can barely be detectable in normal
liver, making it a promising biomarker for the diagnosis
and therapeutic targeting of liver cancer [30].
LncRNA for β-catenin methylation (lnc-β-Catm)
lncRNA for β-catenin methylation (lnc-β-Catm) is an over-
expressed lncRNA identified in LCSCs [31]. lnc-β-Catm is
localized to the chromosome 1q between interferon regula-
tory factor 2 binding protein 2 (IRF2BP2) and translocase
of outer mitochondrial membrane 20 (TOMM20) genes
with a size of 2281 nt and contains two exons [31]. lnc-β-
Catm regulates the self-renewal of LCSCs via activating the
Wnt signaling [31]. lnc-β-Catm mediates the formation of a
RNA-protein complex consisting of β-catenin and enhancer
of zeste homolog 2 (EZH2) in which β-catenin is methyl-
ated by EZH2 [31]. This leads to increased stability of β-
catenin and eventually triggers activation of Wnt signaling
pathway [31]. Patients with high levels of lnc-β-Catm have
a relatively poorer prognosis [31].
LncRNA calmodulin binding transcription activator 1
(CAMTA1)
lncRNA CAMTA1 is highly expressed in HCCs and LCSCs
[32]. Using gain- and loss-of-function studies, it was found
that lncRNA CAMTA1 was essential for the maintenance
of the CSC properties in HCC through regulating the
expression of calmodulin binding transcription activator 1
(CAMTA1) [32]. Direct binding of lncCAMTA1 to the
CAMTA1 promoter changes the chromatin structure and
inhibits the transcription of CAMTA1 as confirmed by
chromatin isolation by the RNA purification Assay
(CHIRP) [32]. Inhibition of CAMTA1 facilitates the main-
tenance of cancer stem cell-like properties [32]. The essen-
tial oncogenic role of lncRNA CAMTA1 in liver cancer
was further supported by the finding that patients with
higher levels of lncRNA CAMTA1 have shorter survival
and an increased rate of early recurrence [32].
LncRNA DANCR
lncRNA differentiation antagonizing non-protein coding
RNA (DANCR) is a lncRNA with significant up-regulation
in HCC and LCSCs [76, 77]. DNACR is involved in the
maintenance and regulation of the stemness feature of
LCSCs [77]. More mechanistic studies have shown that
DNACR promotes HCC via acting as a ceRNA since it
competitively impairs the binding between CTNNB1 (β-ca-
tenin) and miRNA (miR-214, miR-320a and miR-199a),
leading to increased CTNNB1 stability [77]. Patients with
DANCR overexpression often show increased rates of
tumour recurrence and poor survival [77].
Plasmacytoma variant translocation 1 (PVT1)
lncRNA plasmacytoma variant translocation 1 (PVT1) is an
oncofetal lncRNA with increased expression and an onco-
genic role in many solid tumours (e.g., cervical, gastric, colo-
rectal, esophageal, pancreatic, non-small cell lung, ovarian,
bladder and thyroid cancers as well as in acute promyelocytic
leukemia) [78–87]. Overexpression of lncPVT1 has been
found not only in pre-cancerous liver conditions such as
inactivated hepatic stellate cells (HSCs) and fibrotic liver tis-
sues [88], but also in adult HCC [89]. In the development of
liver fibrosis, lncPVT1 competitively binds to miR-152 to
promote liver fibrosis via the Hedgehog (Hh) and EMT path-
way [90]. In the development of liver cancer, both in vivo
and in vitro studies demonstrate that lncPVT1 can prompt
the proliferation and stem cell-like features of liver cancer
cells by stabilizing an RNA binding protein named nucleolar
protein (NOP2) [89]. Clinically, lncPVT1 is positively associ-
ated with tumour size, tumour stage and HBV infection [89].
Clinical implications of lncRNAs in the early diagnosis and
survival prediction
Early diagnosis and intervention remains the most effect-
ive approach to achieving a better outcome for HCC [91].
In this aspect, sensitive and specific markers for early
diagnosis are urgently required. Alpha fetal protein (AFP)
has been widely used as a diagnostic marker for HCC, but
its sensitivity and specificity are suboptimal [92, 93].
lncRNAs with a significantly aberrant expression profile in
HCC tissues as opposed to healthy liver may hold great
potential as diagnostic markers [94]. Some lncRNAs may
be stably present in body fluids such as plasma and their
expression levels are consistently associated with the pro-
gression of HCC [94]. These lncRNAs hold potential value
as diagnostic markers for HCC [94].
HULC is an up-regulated lncRNA in HCC. Meanwhile,
high levels of HULC has been detected in the plasma of
HCC patients with higher Edmondson grades. Hence, it was
proposed that HULC may possess diagnostic value [95].
Through screening blood samples of HCC patients by
microarray, an expression profile of circulating lncRNAs has
been established [96]. By qRT-PCR assay, three novel
lncRNAs (RP11-160H22.5, XLOC-014172 and LOC149086)
were shown to be significantly up-regulated in liver and
matched plasma from HCC patients [96]. Furthermore, in-
creased expression of XLOC-014172 and LOC149086 was
found to be predictors for HCC metastasis [96].
The above lncRNAs are stably present in patient serum
and possess moderate specificity (73%) and sensitivity
(82%) for HCC [96]. Hence, they have potential either
alone or more likely in combination with other variables
as biomarkers for diagnosis and monitoring.
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Prospective and conclusion
With the application of high-throughput sequencing, a
tremendous number of newly identified dysregulated
lncRNAs are reported every year. At present, more than
30,000 dysregulated lncRNAs have been identified in
humans and the number is still increasing as a result of
improved screening technology [8, 97]. Of the large num-
ber of lncRNAs identified so far, some (e.g., TUG1 and
HOTAIR) have been shown to play very important roles
in multiple aspects of liver cancer [65, 73] such as
tumourigenesis, tumour recurrence and drug resistance
(Table. 1). Some lncRNAs (e.g., lncBRM, lncTCF7 and
PVT1) play regulatory roles in the maintenance of stemness
properties of LCSCs and hence may have a role in tumour
initiation [29, 30, 89] (Table. 1). Other lncRNAs (e.g.,
HULC) have potential to serve as diagnostic markers [95].
However, detailed clarification of the roles of lncRNAs in
liver cancer is lacking, partially because lncRNAs have
more complicated functions and multiple modes of func-
tions [98]. Besides, unlike mRNAs, lncRNAs are not
Table 1 Deregulated lncRNAs in HCC
lncRNAs Function Mechanisms References
Up-regulated ANRIL Promotes cell proliferation Interacts with PRC2 to silent KLF2 [43]
MALAT1 Induces apoptosis, activates
mTOR pathway
Increases the splicing factor SRSF1 [45]
PCNA-AS1 Promotes tumour growth Forms a duplex with PCNA, increases PCNA stability [46]
CCAT1 Promotes cell proliferation
and migration
Binds let-7 as a ceRNA [48]
Unigene56159 Induces EMT and migration Binds miR-140-5p as a ceRNA [49]
TP73-AS1 Promotes cell proliferation Competes with HMGB1 to bind miR200a,
activate HMGB1/RAGE axis
[52]
CCAT2 Promote cell proliferation,
EMT and reduces apoptosis
Up-regulates Snail2 [53, 59]
uc.338 Promotes cell proliferation Interacts with BMI1 [54]
UCA1 Promotes invasion and EMT Interacts with miR-203, regulates the expression of Snail2 [58]
SPRY4-IT1 Promotes EMT Up-regulates twist1 and Vimentin, reduces the
expression of E-cadherin
[60]
SNHG20 Promotes EMT Up-regulates twist1 and Vimentin, reduces the
expression of E-cadherin
[61, 62]
TUG1 Induces drug resistance Regulates the expression of P-gp and MDR1 [65]
HULC Induces resistance to oxaliplatin,
5-FU and THP
Activates autophagy [67]
HOTAIR Damages DNA repair and induces MSI Reduces the recruitment of P300, RNA Pol II and
CREB to SETD2 promoter
[73]
lncBRM Maintains stemness and properities
of LCSCs
Interacts with BRM and activates YAP1 signalling [29]
CUDR Promotes growth of LCSCs Up-regulates CyclinD1, down-regulated PTEN [74]
lncTCF7 Promotes self-renewal and
propagation of CSCs
Recruits SWI/SNF complex, activates Wnt pathway [30]
lnc-β-catenin Regulates self-renewal of LCSCs Mediates the formation of β-catenin -EZH2
complex, activates Wnt signalling
[31]
lncRNA CAMTA1 Maintains CSC properties Regulates the expression of CAMTA1 [32]
lncRNA DANCR Maintains stemness of LCSCs Impairs interaction between CTNNB1 and
miRNA as a ceRNA
[77]
PVT1 Promotes cell proliferation and
stem cell-like features
Stabilizes NOP2 [89]
Down-regulated H19 Mediates metastasis of HCC Binds hnRNP U/PCAF/RNA Pol II complex to
increase the expression of miR-200 family
[44]
BANCR Promotes cell proliferation [55]
lnc-FTX Modulate cell proliferation Interacts with MCM2 and binds miR-374a
as a ceRNA
[56]
lnc-DILC Promotes expansion of LCSCs Inhibits IL-6/JAK2/STAT3 [28]
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conserved across the species making it difficult for translat-
ing the data from the animal models to humans [35].
In terms of clinical applications, although some
lncRNAs (e.g.,HULC) have shown their potential in the
early diagnosis and prognosis prediction for patients
with liver cancer [95], large scale clinical studies in liver
cancer patients with various etiologies are needed to fur-
ther validate their efficacy, and more studies are needed
to explore the lncRNAs that might serve as the more
specific and sensitive markers for the diagnosis and ther-
apy for liver cancer.
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